6. Soppina, V., Rai, A.K., Ramaiya, A.J., Barak APP is the founding member of a small family of type I integral membrane proteins, which includes APLP1 and APLP2 (human), Appl (fly) and APL-1 (worm) [1] . The physiological functions of these proteins remain unclear, although they likely include trophic and cell adhesion roles in nerve cells. All of these proteins possess large extracellular domains, which undergo sequential proteolytic processing by different secretase enzymes, and a short cytoplasmic region, which contributes to their complex trafficking itineraries. APP is first cleaved within the lumenal domain by a-secretase (BACE-2 or one of several members of the ADAM metalloproteinase family), or b-secretase (BACE1), resulting in the shedding of almost the entire ectodomain and generation of membrane-tethered APPa or APPb carboxy-terminal fragments [2] [3] [4] . The b-derived fragments are subsequently cleaved within their transmembrane domains by the g-secretase complex to release the amyloidogenic Ab peptide, and a cytoplasmic APP intracellular domain (AICD). The intracellular localisation and trafficking of APP is complicated, with APP found variously at the Golgi, trans-Golgi network (TGN), endosomes and the plasma membrane, where it is endocytosed within clathrin-coated vesicles through an interaction with transport vesicle proteins, such as FE65 [5] [6] [7] . g-secretase has been proposed to be localised in all the same compartments as APP, as well as in the endoplasmic reticulum (ER) and the ER-Golgi intermediate compartment (ERGIC) . The interplay between the localisation of APP and of secretase is critical for determining the degree of Ab production, and as such it is vital that we gain a better understanding of APP and a-, b-and g-secretase trafficking. A recent study from the laboratories of Juan Bonifacino and James Hurley, published in Developmental Cell [8] , describes important new work on exactly these issues, and also contributes valuable knowledge to the wider field of general membrane trafficking, in particular regarding the molecular mechanisms of cargo recognition during transport vesicle formation.
The AP adaptor protein family comprises five heterotetrameric complexes [9] : the clathrin adaptors AP1, AP2 and AP3; the b,g,d,z subcomplex of the coat protein complex COPI; and the most recently discovered member AP4 [10] , which is closely related to AP1-3. Unlike AP1-3, AP4 does not appear to bind clathrin through an LFxFD motif (where F is any bulky hydrophobic side chain) in the linkers of its two large subunits -3 and b -although it seems likely that it can bind to [ED]xxxL[LI] trafficking motifs through the s subunit. The m subunits of AP1-3 bind with K d s in the range of 1-20 mM to the very well-characterised YxxF motifs that are found in unstructured regions of the cytoplasmic regions of many transmembrane protein cargoes [11] . In the recent work, Burgos et al. [8] show that the m subunit of AP4 (m4), while showing only very weak binding to canonical YxxF motifs, binds to similar Yx [FYL] [FL]E motifs with a K d of around 30 mM. Most importantly, however, the high-resolution X-ray crystallography structure of m4 in a complex with a Yx [FYL] [FL]E motif shows that m4 recognises its cognate binding sequence at an entirely different site, in fact on the opposite face of the m4 subunit from that at which YxxF motifs would be expected to bind ( Figure 1A) . The exact sequence used in the structure determination was the YKFFE motif of human APP, and conserved peptides from APLP1 and APLP2 (YKYLE and YRFLE, respectively) are also able to bind this region of m4. Although the m subunits of AP1-3 are lacking the residues important for Yx [FYL] [FL]E binding and indeed, as shown by the authors, do not show significant binding to such motifs, the cargo-binding surface shows substantial conservation amongst all m subunits. This work therefore identifies a new potential cargo-binding site that could be used to bind alternative cargoes by the m subunits of AP1-3, the d COPI subunit and other vesicle trafficking proteins that contain m homology domains, including stonin [12] and FCHo1 and 2 [13] .
The second major finding of this integrated structural and functional study has important implications for our understanding of APP trafficking and secretase localisation. Immunofluorescence microscopy studies showed that, in around 75% of cells, wild-type CFP-tagged APP localised to endosomes, whilst AP4 was found at the TGN. The predominant steady-state membrane localisation of a transport vesicle coat protein generally identifies the site where it regulates the formation of cognate transport vesicles (e.g. AP2, plasma membrane; GGA adaptor proteins, TGN; and COPII, ER/ERGIC), suggesting that AP4 is a component of vesicles that leave the TGN. Since either mutation of the YKFFE motif in APP or depletion of m4 by siRNA each resulted in redistribution of APP to the TGN, the authors conclude that the AP4-derived vesicles regulate transport of APP from the TGN to the endosomal system (Figure 1) . The subsequent observation that the redistribution of APP to the TGN results in increased Ab secretion and AICD production due to enhanced g-secretase cleavage lends support to the idea that a significant fraction of b-and g-secretase activity and subsequent amyloidogenic Ab production occurs in the Golgi, although it will be important to determine whether this also occurs in the physiological context of a neuronal cell.
Taken together, the data presented in the study by Burgos et al. [8] suggest that a major role of AP4 may be to promote transport of a significant fraction of APP, or its carboxy-terminal fragments, to early endosomes, diverting these proteins away from a major site of b-and g-secretase cleavage activity. In doing so, the AP4-mediated trafficking route may effectively confer protection against Ab production and thus reduce the risk of Alzheimer's disease. One prediction from this model is that defects in AP4 function may predispose people to Alzheimer's, and it will be of great interest to see if this turns out to be the case either in patients or in AP4-deficient animal models.
Given that the processing of APP down the amyloidogenic or non-amyloidogenic routes is dependent on the spatial and temporal coincidence of APP and its various processing proteases, it is clear that APP and secretase trafficking is critical for regulating the severity of APP breakdown to the toxic Ab peptide. In many ways, Alzheimer's disease can be considered as a disease of membrane trafficking. Recent years have seen the identification of a number of protein coats that directly and indirectly regulate sorting of APP and secretases between intracellular organelles [5, 6, 14] including: the GGA clathrin adaptors at the TGN; retromer and the associated sorting nexin SNX1 at endosomes [15] ; FE65 [16] and SNX17 [17] , which each bind to APP via an NPxY motif to regulate APP endocytosis and endosomal recycling, respectively; and the AP1 complex, which controls basolateral sorting of APP via a membrane-proximal tyrosine-containing sequence [18] ( Figure 1B) . Interestingly, while retromer and SNX17 each regulate an opposing pathway from that regulated by AP4, namely egress of APP from endosomes, they also appear to play a similar protective role in reducing APP processing to Ab, suggesting a highly complicated relationship between APP localisation and Ab production. The work by Burgos et al. [8] now places AP4 alongside these other intracellular trafficking proteins as an important new player in the Alzheimer's story, and dissection of the relative contributions of these different pathways to APP processing and Alzheimer's disease is developing as a critical field of investigation. Certain secreted proteins bypass the canonical exit pathway from cells. Two studies now shed light on the unconventional secretion route taken by the yeast acyl-coenzyme A-binding protein: this protein is sequestered into autophagic vesicles that are re-routed to the plasma membrane where their content is released to the extracellular space.
Hilde Abrahamsen 1,2 and Harald Stenmark 1,2, * Most proteins that are secreted into the extracellular space utilize the conventional route, in which proteins are directed through the endoplasmic reticulum (ER) and Golgi prior to their release. A common feature of proteins secreted through this pathway is the presence of a signal peptide that is recognized by the signal-recognition particle for transport into the ER once it has been synthesized by the ribosome. After reaching the ER lumen, signal peptides are proteolytically cleaved and the newly synthesized proteins are further trafficked along the secretory pathway to the Golgi apparatus by coat protein II (COPII)-coated vesicles that form at specialized ER exit sites (Figure 1, pathway A) . In the Golgi and trans-Golgi network, the proteins are modified and processed before they are delivered to the extracellular environment in a regulated or
